Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration 2023-10-17 08:00
Abbisko will debut two blockbuster clinical research results at the 2023 European Society for Medical Oncology（ESMO） 2023-10-16 21:50
New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to be Presented at the ESMO 2023 2023-10-16 21:10
TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment 2023-10-16 21:00
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 2023-10-16 20:00
SeekIn Presents New Validation Studies of OncoSeek Multi-cancer Early Detection test at Early Detection of Cancer Conference in London 2023-10-16 20:00
Abbisko presented two preclinical research results at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR) 2023-10-16 18:20
CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China 2023-10-16 13:38
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL 2023-10-16 09:23
Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement 2023-10-13 23:26
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston 2023-10-13 20:00
Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata 2023-10-13 20:00
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023-10-13 09:00
Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE 2023-10-13 08:22
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy 2023-10-13 03:00
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival 2023-10-12 20:50
Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201) 2023-10-12 20:00
MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate 2023-10-12 19:00
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 2023-10-12 19:00
Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress 2023-10-12 18:49
1 57 58 59 60 61 431